Persistent Depressive Disorder (Dysthymia)

Persistent Depressive Disorder (PDD), historically called dysthymia, is a chronic, low-grade depressive illness lasting at least 2 years in adults. Its hallmark is chronicity over severity — patients are rarely incapacitated on any single day but are dysphoric for years, often labelling themselves as "always having been this way". For NEET PG, the single most tested fact is the 2-year minimum duration criterion and its distinction from major depressive disorder (MDD), adjustment disorder, and cyclothymia.

Definition & nosological evolution

PDD is a unipolar mood disorder characterised by a depressed mood for most of the day, for more days than not, persisting ≥ 2 years, accompanied by at least two of a set of associated symptoms, without a symptom-free interval longer than 2 months.

In DSM-5 (2013), the older categories of chronic major depressive disorder and dysthymic disorder (from DSM-IV) were merged into a single entity: Persistent Depressive Disorder (Dysthymia). This is a frequent exam point — DSM-5 consolidated two prior diagnoses into one.

In ICD-11, the equivalent entity is termed Dysthymic disorder, again requiring a ≥ 2-year course of persistent depressive mood that is not sufficiently severe, or episodes not sufficiently prolonged, to meet the criteria for a depressive episode.

High-yield: PDD = depressed mood ≥ 2 years in adults (≥ 1 year in children and adolescents, where the mood may present as irritability rather than sadness).

Diagnostic criteria (DSM-5) at a glance

Criterion	Requirement
A	Depressed mood most of the day, more days than not, ≥ 2 years (≥ 1 yr in children/adolescents; mood may be irritable)
B	≥ 2 of: poor appetite/overeating; insomnia/hypersomnia; low energy/fatigue; low self-esteem; poor concentration or indecisiveness; hopelessness
C	During the 2-year period, never without symptoms in A & B for > 2 months at a time
D	MDD criteria may be continuously present for 2 years (chronic MDD now subsumed under PDD)
E	Never met criteria for cyclothymic disorder; no manic/hypomanic episode
F	Not better explained by a persistent psychotic disorder
G	Not due to a substance or medical condition
H	Causes clinically significant distress or impairment

A useful Criterion-B mnemonic — "ACHEWS" — Appetite change, Concentration poor, Hopelessness, Energy low, Worthlessness (low self-esteem), Sleep change. Need ≥ 2 to qualify.

High-yield: The "no symptom-free interval > 2 months" clause is what distinguishes the persistent nature of PDD from recurrent discrete MDD episodes that fully remit.

Etiology & pathophysiology

PDD is multifactorial, with a stronger contribution from temperament and early adversity than acute MDD.

• Genetic / familial: High familial loading — first-degree relatives have increased rates of both PDD and MDD; overlaps genetically with major depression.
• Neurobiology: Dysregulation of serotonergic (5-HT) and noradrenergic systems; HPA-axis dysregulation with blunted but persistent cortisol abnormalities; reduced hippocampal volume on chronic illness.
• Temperament: Negative affectivity (neuroticism) is a strong predictor.
• Psychosocial: Childhood adversity, chronic stressors, loss of a parent, and ongoing interpersonal difficulties. Chronic medical illness and other psychiatric comorbidity (anxiety, substance use, personality disorders) frequently coexist.

Epidemiologically, lifetime prevalence is roughly 3–6%, with a female-to-male ratio of ~2:1 (as in MDD). Onset is typically early and insidious — childhood, adolescence, or early adulthood — which is why patients describe lifelong low mood.

Clinical features

The clinical picture is one of grumbling, smouldering depression:

• Pervasive gloom, pessimism, joylessness; anhedonia is usually less prominent than in melancholic MDD.
• Low self-esteem, feelings of inadequacy, brooding over the past.
• Fatigue, low energy, poor concentration, indecisiveness.
• Appetite and sleep changes in either direction.
• Social withdrawal, irritability, reduced productivity at work.
• Suicidal ideation can occur and must be screened for despite the "mild" label — chronicity itself is a risk factor.

Crucially, functioning is preserved enough that the patient continues to work/study, but at a chronically reduced level. Patients often present late, attributing symptoms to personality ("I'm just a pessimist").

DSM-5 specifiers

PDD carries specifiers indicating its relationship to major depressive episodes:

• With pure dysthymic syndrome — full MDD criteria not met in the preceding 2 years.
• With persistent major depressive episode — full MDD criteria met throughout the 2 years (the old "chronic MDD").
• With intermittent major depressive episodes, with current episode.
• With intermittent major depressive episodes, without current episode.

Additional specifiers: early onset (< 21 yr) vs late onset (≥ 21 yr); with anxious distress; with atypical features; severity.

The "Double Depression" concept

Double depression = a major depressive episode superimposed on pre-existing dysthymia/PDD. The patient has chronic low-grade depression for years and then develops a full-blown major depressive episode on top of the baseline.

Baseline dysthymia (≥ 2 yr) → superimposed MDE → partial recovery back to dysthymic baseline (not euthymia)

High-yield: Double depression patients have poorer prognosis, lower rates of full inter-episode recovery, and higher relapse, because after the acute episode resolves they fall back only to their chronic dysthymic baseline, not to euthymia.

Diagnosis & investigations

PDD is a clinical diagnosis based on a careful longitudinal history; there is no confirmatory laboratory test. The key diagnostic act is establishing the ≥ 2-year chronic course and excluding mimics.

Investigation of choice = thorough psychiatric history + mental status examination, supplemented by:

• Rating scales: PHQ-9, Hamilton Depression Rating Scale (HAM-D), Beck Depression Inventory — for severity and monitoring, not diagnosis.
• Rule out organic mimics: TSH/free T4 (hypothyroidism), haemoglobin and B12/folate (anaemia, deficiency), fasting glucose, and a basic metabolic panel. Screening for hypothyroidism is essential before labelling chronic low mood as primary PDD.
• Substance/medication review: alcohol, beta-blockers, corticosteroids, interferon, reserpine.

High-yield: Always exclude hypothyroidism and substance use before diagnosing PDD — these are the classic organic mimics of chronic low mood.

Key differential diagnosis

Disorder	Duration / pattern	Mood quality	Distinguishing feature
PDD (Dysthymia)	≥ 2 yr chronic, no gap > 2 mo	Mild–moderate depression	Chronic, low-grade, functioning preserved
Major Depressive Disorder	≥ 2 weeks, episodic, fully remits	Moderate–severe	Discrete episodes; anhedonia, neurovegetative signs prominent
Adjustment disorder with depressed mood	Within 3 months of stressor; resolves within 6 months of stressor ending	Reactive low mood	Clear identifiable stressor; short, self-limiting
Cyclothymic disorder	≥ 2 yr	Alternating subsyndromal hypomanic + depressive symptoms	Mood swings up and down; never full mania/MDE
Bipolar II / Bipolar I	Episodic	Hypomania/mania + depression	History of (hypo)mania excludes PDD
Depression due to hypothyroidism	Variable	Low mood + somatic	Raised TSH, cold intolerance, weight gain, bradycardia

High-yield (NEET PG favourite):

• Adjustment disorder → tied to a stressor, begins within 3 months, resolves within 6 months of the stressor's end.
• Cyclothymia → ≥ 2 years of mood swinging both ways (subthreshold hypomania and depression); the presence of any hypomanic feature excludes PDD.
• PDD → unidirectional, chronic low mood ≥ 2 years.

A clean decision rule: chronic low mood + any (hypo)manic feature → think cyclothymia/bipolar spectrum, not PDD.

Management

The evidence-based approach mirrors MDD treatment but emphasises longer duration because the illness is chronic. The most effective strategy is combined pharmacotherapy + psychotherapy, which outperforms either alone for chronic depression.

Stepwise approach:

1. Confirm diagnosis and screen for/treat comorbidity (anxiety, substance use), suicidality, and organic mimics.
2. First-line drug — an SSRI (e.g., fluoxetine, sertraline, escitalopram) → favourable safety and tolerability.
3. Add structured psychotherapy — CBT and the Cognitive Behavioural Analysis System of Psychotherapy (CBASP), the latter developed specifically for chronic depression; interpersonal therapy (IPT) is also used.
4. If inadequate response → switch SSRI, or move to an SNRI (venlafaxine, duloxetine), mirtazapine, bupropion, or TCAs.
5. Maintain treatment long-term given the chronic, relapsing course.

Drug class	Examples	Notes
SSRI (first-line)	Fluoxetine, sertraline, escitalopram	Best tolerated; preferred start
SNRI	Venlafaxine, duloxetine	Useful with comorbid pain/anxiety
Atypical	Mirtazapine, bupropion	Mirtazapine for insomnia/poor appetite; bupropion if fatigue/sexual side-effect concerns
TCA	Imipramine, amitriptyline	Effective but more side-effects; cardiotoxic in overdose

High-yield: SSRIs are first-line for PDD. For chronic depression specifically, combined pharmacotherapy + psychotherapy (notably CBASP) gives the best outcomes.

High-yield: Allow an adequate antidepressant trial of 6–8 weeks at therapeutic dose before declaring treatment failure — premature switching is a common error tested in clinical vignettes.

Course, prognosis & complications

• Course: Chronic and insidious; symptoms may wax and wane over years to decades.
• High risk of conversion: A large proportion of PDD patients eventually develop a superimposed MDE (double depression), and many ultimately develop full MDD over their lifetime.
• Prognosis: Generally guarded because of chronicity; double depression worsens it. Early onset (< 21 yr) predicts a more chronic course and higher comorbidity.

Complications:

• Progression to double depression / recurrent MDD.
• Suicide and self-harm — chronic hopelessness is an independent risk.
• Substance use disorders (self-medication).
• Marital, occupational, and social impairment from cumulative chronic dysfunction.
• Comorbid anxiety disorders and personality pathology.

Recently asked / exam angle

• Minimum duration criterion is the classic single-best-answer stem: "A 32-year-old reports feeling low for the past 3 years, still goes to work, never symptom-free for more than a few weeks, no episodes of elation — diagnosis?" → Persistent depressive disorder (dysthymia).
• 2 years (adults) vs 1 year (children/adolescents) is a frequent distractor pair.
• Double depression definition — "MDE superimposed on dysthymia" — appears as a one-liner factual question.
• Differentiation from adjustment disorder (stressor-linked, < 3 months onset, resolves within 6 months) and cyclothymia (bidirectional subthreshold mood swings ≥ 2 yr) is a recurring "which is NOT consistent with PDD" style item.
• DSM-5 merge — dysthymic disorder + chronic MDD → PDD — has been asked as a nosology fact.
• First-line drug = SSRI, and the role of CBASP in chronic depression, are management-based stems.
• Distinguishing PDD from MDD on the basis of chronicity over severity and preserved functioning.

Rapid revision

1. PDD = chronic depressed mood ≥ 2 years in adults; ≥ 1 year in children/adolescents (may be irritable mood).
2. Need ≥ 2 Criterion-B symptoms (appetite, sleep, energy, self-esteem, concentration, hopelessness) — mnemonic ACHEWS.
3. No symptom-free interval > 2 months during the 2-year period.
4. DSM-5 merged dysthymic disorder + chronic MDD → Persistent Depressive Disorder; ICD-11 = dysthymic disorder.
5. Double depression = MDE superimposed on baseline dysthymia → worse prognosis, falls back only to dysthymic baseline.
6. Female:male ≈ 2:1; early, insidious onset; lifetime prevalence ~3–6%.
7. Diagnosis is clinical — exclude hypothyroidism (TSH) and substance use first.
8. Adjustment disorder → stressor-linked, onset < 3 mo, resolves < 6 mo after stressor; cyclothymia → bidirectional subthreshold mood ≥ 2 yr.
9. Any (hypo)manic feature excludes PDD → think bipolar spectrum/cyclothymia.
10. First-line drug = SSRI; best outcomes with pharmacotherapy + psychotherapy (CBASP/CBT).
11. Allow 6–8 weeks adequate antidepressant trial before switching.
12. Screen for suicidality — chronicity and hopelessness are real risks despite the "mild" label.